Home » Archive

News

Original content and news from BioSpace, Xconomy, Marketwire and other sources, specific to the region.

News, Syndication »

Faculty want Scripps Research chief out

Posted by sandiegobiotech July 3rd, 2014 .
No Comments

Faculty leaders have sent an email calling for removal of President Michael Marletta.

More...

News, Syndication »

West Coast Biotech Roundup: Seragon, Ambrx, Pregenen, and More

Posted by sandiegobiotech July 3rd, 2014 .
No Comments

Our nominee for the just-created “Bio Man with the Midas Touch” award goes to Richard Heyman, who co-founded San Diego’s Seragon Pharmaceuticals 11 months ago. Roche’s Genentech unit agreed yesterday…

[[Click headline to continue reading.]]

More...

News, Syndication »

Scripps Research meeting minutes

Posted by sandiegobiotech July 2nd, 2014 .
No Comments

Meeting minutes outline TSRI’s partnership strategy.

More...

News, Syndication »

Scripps Research projects $21M deficit

Posted by sandiegobiotech July 2nd, 2014 .
No Comments

Institute President Michael Marletta says center remains on solid financial footing.

More...

News, Syndication »

Artificial embryonic stem cells have quality problems: study

Posted by sandiegobiotech July 2nd, 2014 .
No Comments

Induced pluripotent stem cells have quality concerns, which may hinder use for therapy.

More...

News, Syndication »

Meet our team: Rhiannon Bruni

Posted by sandiegobiotech July 2nd, 2014 .
No Comments

This is an interview with Rhiannon Bruni, senior communications specialist at our La Jolla, Calif., campus.

More...

News, Syndication »

Seragon purchased for up to $1.7 billion

Posted by sandiegobiotech July 2nd, 2014 .
No Comments

San Diego developer of breast cancer drugs, was spun out of Aragon Pharma last year.

More...

News, Syndication »

VenBio Scores Again as Genentech Pays $1.7B+ for Seragon Pharma

Posted by sandiegobiotech July 2nd, 2014 .
No Comments

The big year for San Francisco, CA-based life sciences venture firm venBio just got bigger. Genentech, the big cancer drugmaker from the Bay Area, has agreed to buy a less than one-year-old San…

[[Click headline to continue reading.]]

More...

News, Syndication »

Synchroneuron Nets $20M to Combat Drug-Induced Movement Disorder

Posted by sandiegobiotech July 2nd, 2014 .
No Comments

With a few tweaks, Synchroneuron believes it’s been able to turn an old, flawed drug for alcoholism into a new one for a completely different disorder. Now the Waltham, MA-based startup has just…

[[Click headline to continue reading.]]

More...

News, Syndication »

Some stem cell methods closer to “gold standard” than others

Posted by sandiegobiotech July 1st, 2014 .
No Comments

LA JOLLA—Researchers around the world have turned to stem cells, which have the potential to develop into any cell type in the body, for potential regenerative and disease therapeutics.

More...